Cargando…

Selective Inhibition of the C-Domain of ACE (Angiotensin-Converting Enzyme) Combined With Inhibition of NEP (Neprilysin): A Potential New Therapy for Hypertension

Combined inhibition of NEP (neutral endopeptidase) and ACE (angiotensin-converting enzyme), without unwanted effects, remains an attractive therapeutic strategy in cardiovascular medicine. Omapatrilat, a dual NEP inhibitor–ACE inhibitor, was a promising antihypertensive drug but failed in trials due...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alves-Lopes, Rhéure, Montezano, Augusto C., Neves, Karla B., Harvey, Adam, Rios, Francisco J., Skiba, Dominik S., Arendse, Lauren B., Guzik, Tomasz J., Graham, Delyth, Poglitsch, Marko, Sturrock, Edward, Touyz, Rhian M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357049/ https://www.ncbi.nlm.nih.gov/pubmed/34304582 http://dx.doi.org/10.1161/HYPERTENSIONAHA.121.17041

Ejemplares similares

Role of PARP and TRPM2 in VEGF Inhibitor‐Induced Vascular Dysfunction
por: Neves, Karla B., et al.
Publicado: (2023)

Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure
por: Arendse, Lauren B., et al.
Publicado: (2019)

Vasoprotective effects of NOX4 are mediated via polymerase and transient receptor potential melastatin 2 cation channels in endothelial cells
por: Alves-Lopes, Rheure, et al.
Publicado: (2023)

Oxidative Stress: A Unifying Paradigm in Hypertension
por: Touyz, Rhian M., et al.
Publicado: (2020)

Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin—Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme
por: Sharma, Urvashi, et al.
Publicado: (2020)

Muscarinic Receptor Type-3 in Hypertension and Cholinergic-Adrenergic Crosstalk: Genetic Insights and Potential for New Antihypertensive Targets
por: Alves-Lopes, Rhéure, et al.
Publicado: (2019)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
por: Dizaye, Kawa, et al.
Publicado: (2019)

Angiotensin converting enzyme gene polymorphism and influence of ACE inhibition
por: Arman, Q.
Publicado: (2010)

Novel mechanism of inhibition of human angiotensin-I-converting enzyme (ACE) by a highly specific phosphinic tripeptide
por: Akif, Mohd, et al.
Publicado: (2011)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
por: Esser, Nathalie, et al.
Publicado: (2022)

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020)

Anti‐atherosclerotic effect of the angiotensin 1–7 mimetic AVE0991 is mediated by inhibition of perivascular and plaque inflammation in early atherosclerosis
por: Skiba, D S, et al.
Publicado: (2017)

Vascular dysfunction and fibrosis in stroke-prone spontaneously hypertensive rats: The aldosterone-mineralocorticoid receptor-Nox1 axis
por: Harvey, Adam P., et al.
Publicado: (2017)

SARS-CoV-2 spike protein induces endothelial inflammation via ACE2 independently of viral replication
por: Montezano, Augusto C., et al.
Publicado: (2023)

Tissue sodium excess is not hypertonic and reflects extracellular volume expansion
por: Rossitto, Giacomo, et al.
Publicado: (2020)

ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease
por: Kuriakose, Jithin, et al.
Publicado: (2021)

New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19
por: El Tabaa, Manar Mohammed, et al.
Publicado: (2020)

Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost
por: Mohammed El Tabaa, Manar, et al.
Publicado: (2020)

Vascular Fibrosis in Aging and Hypertension: Molecular Mechanisms and Clinical Implications
por: Harvey, Adam, et al.
Publicado: (2016)

Role of ACE, ACE2 and Neprilysin in the Kidney
por: Chappell, Mark C.
Publicado: (2007)

Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure
por: Verbrugge, Frederik H., et al.
Publicado: (2020)

Upregulation of Nrf2 and Decreased Redox Signaling Contribute to Renoprotective Effects of Chemerin Receptor Blockade in Diabetic Mice
por: Neves, Karla Bianca, et al.
Publicado: (2018)

Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer’s Disease
por: Grimm, Marcus O. W., et al.
Publicado: (2013)

Molecular and Thermodynamic Mechanisms of the Chloride-dependent Human Angiotensin-I-converting Enzyme (ACE)
por: Yates, Christopher J., et al.
Publicado: (2014)

New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) I: Endogenous Angiotensin Converting Enzyme (ACE) Inhibition
por: Fagyas, Miklós, et al.
Publicado: (2014)

Genomic and non-genomic effects of androgens in the cardiovascular system: clinical implications
por: Lucas-Herald, Angela K., et al.
Publicado: (2017)

Structural basis for the inhibition of human angiotensin‐1 converting enzyme by fosinoprilat
por: Cozier, Gyles E., et al.
Publicado: (2022)

Characterization of the first angiotensin-converting like enzyme in bacteria: Ancestor ACE is already active
por: Rivière, Guillaume, et al.
Publicado: (2007)

Angiotensin Receptor‐Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension
por: Sharifi Kia, Danial, et al.
Publicado: (2020)

Calmodulin interacts with angiotensin‐converting enzyme‐2 (ACE2) and inhibits shedding of its ectodomain
por: Lambert, Daniel W., et al.
Publicado: (2008)

Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study
por: Kovarik, Johannes J., et al.
Publicado: (2021)

Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2
por: Zolfaghari Emameh, Reza, et al.
Publicado: (2020)

Central role of c-Src in NOX5- mediated redox signalling in vascular smooth muscle cells in human hypertension
por: Camargo, Livia L, et al.
Publicado: (2021)

Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides
por: Masuyer, Geoffrey, et al.
Publicado: (2012)

Reduced blood pressure in sickle cell disease is associated with decreased angiotensin converting enzyme (ACE) activity and is not modulated by ACE inhibition
por: Brito, Pamela L., et al.
Publicado: (2022)

Combined angiotensin-converting enzyme and aminopeptidase inhibition for treatment of experimental ventilator-induced lung injury in mice
por: Mao, Xinjun, et al.
Publicado: (2023)

Angiotensin Receptor-Neprilysin Inhibition for Doxorubicin-Mediated Cardiotoxicity: Time for a Paradigm Shift
por: Hahn, Virginia S., et al.
Publicado: (2020)

Manipulating angiotensin metabolism with angiotensin converting enzyme 2 (ACE2) in heart failure
por: Patel, Vaibhav B., et al.
Publicado: (2012)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney
por: Domenig, Oliver, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_giuvrmmj4ohcg2kpsuskl4fn4j